Literature DB >> 27556837

Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series.

Tiong Yeng Lim1, Polychronis Pavlidis, Shraddha Gulati, Tasneem Pirani, Mark Samaan, Guy Chung-Faye, Patrick Dubois, Peter Irving, Michael Heneghan, BuʼHussain Hayee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27556837     DOI： 10.1097/MIB.0000000000000906

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  6 in total

1.  Safety of vedolizumab in liver transplant recipients: A systematic review.

Authors:  Marco Spadaccini; Alessio Aghemo; Flavio Caprioli; Ana Lleo; Federica Invernizzi; Silvio Danese; Maria F Donato
Journal:  United European Gastroenterol J       Date:  2019-06-20       Impact factor: 4.623

2.  Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.

Authors:  Andrew P Wright; Robert J Fontana; Ryan W Stidham
Journal:  Liver Transpl       Date:  2017-07       Impact factor: 5.799

3.  Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

Authors:  B Christensen; D Micic; P R Gibson; A Yarur; E Bellaguarda; P Corsello; J N Gaetano; J Kinnucan; V L Rao; S Reddy; S Singh; J Pekow; D T Rubin
Journal:  Aliment Pharmacol Ther       Date:  2018-01-29       Impact factor: 8.171

Review 4.  Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.

Authors:  Robin J Dart; Mark A Samaan; Nick Powell; Peter M Irving
Journal:  Clin Exp Gastroenterol       Date:  2017-03-03

Review 5.  The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Authors:  Kate D Lynch; Satish Keshav; Roger W Chapman
Journal:  Curr Hepatol Rep       Date:  2019-03-07

6.  Perineural invasion as a prognostic factor in patients with stage I-III rectal cancer - 5-year follow up.

Authors:  Milica Stojkovic Lalosevic; Tamara Milovanovic; Marjan Micev; Mirjana Stojkovic; Sanja Dragasevic; Milos Stulic; Ivan Rankovic; Vladimir Dugalic; Zoran Krivokapic; Aleksandra Pavlovic Markovic
Journal:  World J Gastrointest Oncol       Date:  2020-05-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.